nodes	percent_of_prediction	percent_of_DWPC	metapath
Imatinib—NTRK1—Frs2-mediated activation—FRS2—nasal cavity cancer	0.0488	0.0488	CbGpPWpGaD
Imatinib—NTRK1—Prolonged ERK activation events—FRS2—nasal cavity cancer	0.0459	0.0459	CbGpPWpGaD
Imatinib—NTRK1—Signalling to ERKs—FRS2—nasal cavity cancer	0.0311	0.0311	CbGpPWpGaD
Imatinib—NTRK1—SHP2 signaling—FRS2—nasal cavity cancer	0.0249	0.0249	CbGpPWpGaD
Imatinib—NTRK1—Neurotrophic factor-mediated Trk receptor signaling—FRS2—nasal cavity cancer	0.0239	0.0239	CbGpPWpGaD
Imatinib—PDGFRA—Allograft Rejection—CXCL11—nasal cavity cancer	0.0229	0.0229	CbGpPWpGaD
Imatinib—NTRK1—PI3K/AKT activation—FRS2—nasal cavity cancer	0.016	0.016	CbGpPWpGaD
Imatinib—PDGFRB—SHP2 signaling—FRS2—nasal cavity cancer	0.0156	0.0156	CbGpPWpGaD
Imatinib—ABL1—Neurotrophic factor-mediated Trk receptor signaling—FRS2—nasal cavity cancer	0.0146	0.0146	CbGpPWpGaD
Imatinib—KIT—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0133	0.0133	CbGpPWpGaD
Imatinib—PDGFRA—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0126	0.0126	CbGpPWpGaD
Imatinib—LCK—SHP2 signaling—FRS2—nasal cavity cancer	0.0125	0.0125	CbGpPWpGaD
Imatinib—NTRK1—BDNF signaling pathway—FRS2—nasal cavity cancer	0.012	0.012	CbGpPWpGaD
Imatinib—KIT—PI-3K cascade—FRS2—nasal cavity cancer	0.012	0.012	CbGpPWpGaD
Imatinib—KIT—PI3K/AKT activation—FRS2—nasal cavity cancer	0.0117	0.0117	CbGpPWpGaD
Imatinib—KIT—GAB1 signalosome—FRS2—nasal cavity cancer	0.0116	0.0116	CbGpPWpGaD
Imatinib—PDGFRB—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.0114	0.0114	CbGpPWpGaD
Imatinib—PDGFRA—PI-3K cascade—FRS2—nasal cavity cancer	0.0114	0.0114	CbGpPWpGaD
Imatinib—KIT—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0113	0.0113	CbGpPWpGaD
Imatinib—PDGFRA—PI3K/AKT activation—FRS2—nasal cavity cancer	0.0111	0.0111	CbGpPWpGaD
Imatinib—PDGFRA—GAB1 signalosome—FRS2—nasal cavity cancer	0.011	0.011	CbGpPWpGaD
Imatinib—PDGFRA—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Imatinib—PDGFRB—PI-3K cascade—FRS2—nasal cavity cancer	0.0102	0.0102	CbGpPWpGaD
Imatinib—PDGFRB—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00998	0.00998	CbGpPWpGaD
Imatinib—PDGFRB—GAB1 signalosome—FRS2—nasal cavity cancer	0.0099	0.0099	CbGpPWpGaD
Imatinib—PDGFRB—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00968	0.00968	CbGpPWpGaD
Imatinib—LCK—Constitutive PI3K/AKT Signaling in Cancer—FRS2—nasal cavity cancer	0.00911	0.00911	CbGpPWpGaD
Imatinib—NTRK1—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00903	0.00903	CbGpPWpGaD
Imatinib—KIT—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00896	0.00896	CbGpPWpGaD
Imatinib—ABCB1—Allograft Rejection—CXCL11—nasal cavity cancer	0.00866	0.00866	CbGpPWpGaD
Imatinib—KIT—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00858	0.00858	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00848	0.00848	CbGpPWpGaD
Imatinib—KIT—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00844	0.00844	CbGpPWpGaD
Imatinib—LCK—PI-3K cascade—FRS2—nasal cavity cancer	0.00821	0.00821	CbGpPWpGaD
Imatinib—PDGFRA—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00812	0.00812	CbGpPWpGaD
Imatinib—KIT—Downstream signal transduction—FRS2—nasal cavity cancer	0.00806	0.00806	CbGpPWpGaD
Imatinib—KIT—Signaling by FGFR—FRS2—nasal cavity cancer	0.00802	0.00802	CbGpPWpGaD
Imatinib—LCK—PI3K/AKT activation—FRS2—nasal cavity cancer	0.00801	0.00801	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00799	0.00799	CbGpPWpGaD
Imatinib—KIT—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00798	0.00798	CbGpPWpGaD
Imatinib—LCK—GAB1 signalosome—FRS2—nasal cavity cancer	0.00795	0.00795	CbGpPWpGaD
Imatinib—KIT—DAP12 signaling—FRS2—nasal cavity cancer	0.00794	0.00794	CbGpPWpGaD
Imatinib—KIT—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00783	0.00783	CbGpPWpGaD
Imatinib—LCK—Role of LAT2/NTAL/LAB on calcium mobilization—FRS2—nasal cavity cancer	0.00777	0.00777	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00764	0.00764	CbGpPWpGaD
Imatinib—PDGFRA—Downstream signal transduction—FRS2—nasal cavity cancer	0.00763	0.00763	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by FGFR—FRS2—nasal cavity cancer	0.00759	0.00759	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00755	0.00755	CbGpPWpGaD
Imatinib—PDGFRA—DAP12 signaling—FRS2—nasal cavity cancer	0.00752	0.00752	CbGpPWpGaD
Imatinib—KIT—DAP12 interactions—FRS2—nasal cavity cancer	0.00747	0.00747	CbGpPWpGaD
Imatinib—KIT—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00747	0.00747	CbGpPWpGaD
Imatinib—KIT—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00747	0.00747	CbGpPWpGaD
Imatinib—PDGFRA—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00741	0.00741	CbGpPWpGaD
Imatinib—KIT—Signaling by EGFR—FRS2—nasal cavity cancer	0.00741	0.00741	CbGpPWpGaD
Imatinib—KIT—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00734	0.00734	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00731	0.00731	CbGpPWpGaD
Imatinib—KIT—Signaling by PDGF—FRS2—nasal cavity cancer	0.00731	0.00731	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by ERBB4—FRS2—nasal cavity cancer	0.0072	0.0072	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00707	0.00707	CbGpPWpGaD
Imatinib—PDGFRA—DAP12 interactions—FRS2—nasal cavity cancer	0.00707	0.00707	CbGpPWpGaD
Imatinib—PDGFRA—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00707	0.00707	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by EGFR—FRS2—nasal cavity cancer	0.00701	0.00701	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00695	0.00695	CbGpPWpGaD
Imatinib—NTRK1—Signaling by NGF—FRS2—nasal cavity cancer	0.00695	0.00695	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by PDGF—FRS2—nasal cavity cancer	0.00692	0.00692	CbGpPWpGaD
Imatinib—KIT—B Cell Activation—FRS2—nasal cavity cancer	0.00691	0.00691	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signal transduction—FRS2—nasal cavity cancer	0.00687	0.00687	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR—FRS2—nasal cavity cancer	0.00684	0.00684	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00681	0.00681	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 signaling—FRS2—nasal cavity cancer	0.00677	0.00677	CbGpPWpGaD
Imatinib—PDGFRB—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00668	0.00668	CbGpPWpGaD
Imatinib—KIT—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00662	0.00662	CbGpPWpGaD
Imatinib—PDGFRA—B Cell Activation—FRS2—nasal cavity cancer	0.00655	0.00655	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00637	0.00637	CbGpPWpGaD
Imatinib—PDGFRB—DAP12 interactions—FRS2—nasal cavity cancer	0.00637	0.00637	CbGpPWpGaD
Imatinib—PDGFRB—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00637	0.00637	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR—FRS2—nasal cavity cancer	0.00632	0.00632	CbGpPWpGaD
Imatinib—PDGFRA—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00626	0.00626	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00626	0.00626	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by PDGF—FRS2—nasal cavity cancer	0.00623	0.00623	CbGpPWpGaD
Imatinib—LCK—Signaling by SCF-KIT—FRS2—nasal cavity cancer	0.00613	0.00613	CbGpPWpGaD
Imatinib—PDGFRB—B Cell Activation—FRS2—nasal cavity cancer	0.0059	0.0059	CbGpPWpGaD
Imatinib—LCK—Downstream signaling of activated FGFR—FRS2—nasal cavity cancer	0.00587	0.00587	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB4—FRS2—nasal cavity cancer	0.00578	0.00578	CbGpPWpGaD
Imatinib—PDGFRB—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00564	0.00564	CbGpPWpGaD
Imatinib—LCK—Downstream signal transduction—FRS2—nasal cavity cancer	0.00552	0.00552	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR—FRS2—nasal cavity cancer	0.00549	0.00549	CbGpPWpGaD
Imatinib—LCK—Signaling by ERBB2—FRS2—nasal cavity cancer	0.00546	0.00546	CbGpPWpGaD
Imatinib—LCK—DAP12 signaling—FRS2—nasal cavity cancer	0.00544	0.00544	CbGpPWpGaD
Imatinib—LCK—Downstream signaling events of B Cell Receptor (BCR)—FRS2—nasal cavity cancer	0.00536	0.00536	CbGpPWpGaD
Imatinib—LCK—DAP12 interactions—FRS2—nasal cavity cancer	0.00511	0.00511	CbGpPWpGaD
Imatinib—LCK—Fc epsilon receptor (FCERI) signaling—FRS2—nasal cavity cancer	0.00511	0.00511	CbGpPWpGaD
Imatinib—LCK—Signaling by FGFR in disease—FRS2—nasal cavity cancer	0.00511	0.00511	CbGpPWpGaD
Imatinib—KIT—Signaling by NGF—FRS2—nasal cavity cancer	0.00509	0.00509	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR—FRS2—nasal cavity cancer	0.00507	0.00507	CbGpPWpGaD
Imatinib—LCK—Signaling by EGFR in Cancer—FRS2—nasal cavity cancer	0.00502	0.00502	CbGpPWpGaD
Imatinib—LCK—Signaling by PDGF—FRS2—nasal cavity cancer	0.005	0.005	CbGpPWpGaD
Imatinib—PDGFRA—Signaling by NGF—FRS2—nasal cavity cancer	0.00482	0.00482	CbGpPWpGaD
Imatinib—LCK—B Cell Activation—FRS2—nasal cavity cancer	0.00473	0.00473	CbGpPWpGaD
Imatinib—LCK—NGF signalling via TRKA from the plasma membrane—FRS2—nasal cavity cancer	0.00453	0.00453	CbGpPWpGaD
Imatinib—PDGFRB—Signaling by NGF—FRS2—nasal cavity cancer	0.00434	0.00434	CbGpPWpGaD
Imatinib—LCK—Signaling by NGF—FRS2—nasal cavity cancer	0.00348	0.00348	CbGpPWpGaD
Imatinib—KIT—Innate Immune System—FRS2—nasal cavity cancer	0.0029	0.0029	CbGpPWpGaD
Imatinib—KIT—Adaptive Immune System—FRS2—nasal cavity cancer	0.00279	0.00279	CbGpPWpGaD
Imatinib—PDGFRA—Innate Immune System—FRS2—nasal cavity cancer	0.00275	0.00275	CbGpPWpGaD
Imatinib—PDGFRA—Adaptive Immune System—FRS2—nasal cavity cancer	0.00264	0.00264	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—CXCL11—nasal cavity cancer	0.00253	0.00253	CbGpPWpGaD
Imatinib—PDGFRB—Innate Immune System—FRS2—nasal cavity cancer	0.00248	0.00248	CbGpPWpGaD
Imatinib—ABL1—Innate Immune System—FRS2—nasal cavity cancer	0.00241	0.00241	CbGpPWpGaD
Imatinib—PDGFRB—Adaptive Immune System—FRS2—nasal cavity cancer	0.00238	0.00238	CbGpPWpGaD
Imatinib—LCK—Innate Immune System—FRS2—nasal cavity cancer	0.00199	0.00199	CbGpPWpGaD
Imatinib—LCK—Adaptive Immune System—FRS2—nasal cavity cancer	0.00191	0.00191	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—CXCL11—nasal cavity cancer	0.00185	0.00185	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—CXCL11—nasal cavity cancer	0.00176	0.00176	CbGpPWpGaD
Imatinib—KIT—Immune System—FRS2—nasal cavity cancer	0.00169	0.00169	CbGpPWpGaD
Imatinib—PDGFRA—Immune System—FRS2—nasal cavity cancer	0.0016	0.0016	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—CXCL11—nasal cavity cancer	0.00158	0.00158	CbGpPWpGaD
Imatinib—KIT—Disease—FRS2—nasal cavity cancer	0.00156	0.00156	CbGpPWpGaD
Imatinib—NTRK1—Signaling Pathways—FRS2—nasal cavity cancer	0.00149	0.00149	CbGpPWpGaD
Imatinib—PDGFRA—Disease—FRS2—nasal cavity cancer	0.00148	0.00148	CbGpPWpGaD
Imatinib—PDGFRB—Immune System—FRS2—nasal cavity cancer	0.00144	0.00144	CbGpPWpGaD
Imatinib—ABL1—Immune System—FRS2—nasal cavity cancer	0.00141	0.00141	CbGpPWpGaD
Imatinib—PDGFRB—Disease—FRS2—nasal cavity cancer	0.00133	0.00133	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—CXCL11—nasal cavity cancer	0.00127	0.00127	CbGpPWpGaD
Imatinib—LCK—Immune System—FRS2—nasal cavity cancer	0.00116	0.00116	CbGpPWpGaD
Imatinib—KIT—Signaling Pathways—FRS2—nasal cavity cancer	0.00109	0.00109	CbGpPWpGaD
Imatinib—LCK—Disease—FRS2—nasal cavity cancer	0.00107	0.00107	CbGpPWpGaD
Imatinib—PDGFRA—Signaling Pathways—FRS2—nasal cavity cancer	0.00103	0.00103	CbGpPWpGaD
Imatinib—PDGFRB—Signaling Pathways—FRS2—nasal cavity cancer	0.000932	0.000932	CbGpPWpGaD
Imatinib—LCK—Signaling Pathways—FRS2—nasal cavity cancer	0.000748	0.000748	CbGpPWpGaD
